Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

Medicine, Hematology, Oncology +12

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Improved survival in multiple myeloma and the impact of novel therapies

Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14